The brokerage assigned Dr. Reddy’s Laboratories a goal value of Rs 1,553, implying a 15% potential upside from Tuesday’s closing value.
Revlimid, the most cancers drug accounting for round 40% of Dr. Reddy’s FY24 EBITDA, is predicted to lose patent safety in 2026, posing a big menace to the corporate’s earnings development. Nevertheless, the corporate has been proactive in implementing methods to mitigate this danger. In response to Nuvama, the measures taken recommend a good risk-reward steadiness.
“Revlimid’s patent expiry in 2026 poses a big menace to Dr. Reddy’s earnings development, however we imagine Dr. Reddy’s proactive measures will mitigate about 80% of the anticipated EBITDA affect,” stated Nuvama.
Dr. Reddy’s is ready to launch Semaglutide, a drug concentrating on a $2 billion market, in Canada by January 2026. The early launch will leverage the corporate’s backward integration capabilities, positioning it as a key participant within the phase, in response to Nuvama.
Moreover, the corporate plans to roll out its Abatacept biosimilar within the US, a $2.8 billion market, in FY27. Notably, that is the one biosimilar underneath growth for the fusion protein, signaling sturdy income potential, the brokerage stated. Within the nicotine substitute remedy (NRT) phase, Dr. Reddy’s continues to drive development by new product launches, investments, and cross-market growth.Past its mitigation methods, the Hyderabad-based firm is poised for long-term development in its core markets of India, Russia, and China. Nuvama additionally famous that subject power growth, vaccine distribution alternatives, and the Nestlé three way partnership add additional development levers.Nuvama upgraded its FY27 earnings estimates for Dr. Reddy’s by 15%. The brokerage anticipates that margins will stay throughout the firm’s steerage vary, supported by a discount in R&D expenditure post-2026.
Over the previous 12 months, shares of Dr. Reddy’s have gained over 18%, with the inventory’s Relative Power Index (RSI) presently at 59.7, indicating sturdy momentum.
(Disclaimer: Suggestions, strategies, views and opinions given by the consultants are their very own. These don’t signify the views of Financial Instances)
